- Home
- MPB vs ACRS Comparison
MPB vs ACRS Comparison
Compare MPB & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPB | ACRS |
|---|---|---|
| Founded | 1868 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.5M | 868.5M |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MPB | ACRS |
|---|---|---|
| Price | $36.72 | $6.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $37.00 | $10.20 |
| AVG Volume (30 Days) | 143.7K | ★ 1.9M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ 1.22 | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $30.95 | N/A |
| Revenue Next Year | $9.45 | $4.24 |
| P/E Ratio | $30.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.56 | $1.74 |
| 52 Week High | $39.15 | $6.52 |
Technical Indicators
Market Signals| Indicator | MPB | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | N/A |
| Support Level | $31.20 | N/A |
| Resistance Level | $37.18 | N/A |
| Average True Range (ATR) | 0.64 | 0.00 |
| MACD | -0.25 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout MPB Mid Penn Bancorp
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.